Is dabigatran considered a cost-effective alternative to warfarin treatment: a review of current economic evaluations worldwide.

Hesselbjerg, Louise Justesen

Is dabigatran considered a cost-effective alternative to warfarin treatment: a review of current economic evaluations worldwide. [electronic resource] - Journal of medical economics Jul 2013 - 845-58 p. digital

Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review

1941-837X

10.3111/13696998.2013.800523 doi


Anticoagulants--adverse effects
Atrial Fibrillation--drug therapy
Benzimidazoles--administration & dosage
Cost-Benefit Analysis
Dabigatran
Embolism--prevention & control
Hemorrhage--chemically induced
Humans
Quality-Adjusted Life Years
Stroke--prevention & control
Warfarin--administration & dosage
beta-Alanine--administration & dosage